Alnylam gets first RNAi drug approval

Twenty years after the scientific co-founders of Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) discovered RNAi, a drug using the modality has been approved. On Aug. 10, FDA approved Onpattro patisiran to treat polyneuropathy caused by hereditary transthyretin (TTR)-mediated amyloidosis (hATTR) in adults. The indication is narrower than what Alnylam originally sought -- general treatment of hATTR -- in its NDA for Onpattro,

Read the full 601 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers